Drug Profile
Research programme: sphingosine 1 phosphate receptor antagonists - TME Pharma
Alternative Names: NOX S-91; NOX S-93Latest Information Update: 01 Aug 2022
Price :
$50
*
At a glance
- Originator NOXXON Pharma AG
- Developer TME Pharma
- Class Nucleotide aptamers; Oligonucleotides
- Mechanism of Action Angiogenesis inhibitors; Sphingosine-1-phosphate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Eye disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in Germany